利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.016 秒)

    USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION
    6.
    发明公开
    USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION 审中-公开
    VERWENDUNG VON STING-AGONISTEN ZUR BEHANDLUNG VON CHRONISCHER HEPATITIS-B-VIRUSINFEKTION

    公开(公告)号：EP3060056A2

    公开(公告)日：2016-08-31

    申请号：EP14855900.8

    申请日：2014-10-21

    申请人： Drexel University

    发明人： CHANG, Jinhong ,  GUO, Fang ,  BLOCK, Timothy M. ,  GUO, Ju-Tao

    IPC分类号： A01N43/76 ,  C07D263/30

    CPC分类号： A61K31/352 ,  A61K31/473 ,  C12Q1/706 ,  C12Q2600/136 ,  G01N33/5067 ,  G01N2333/02

    摘要： Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

    摘要翻译： 本发明包括治疗患有乙型肝炎病毒（HBV）感染的受试者的方法。 在某些实施方案中，本发明的方法包括用小分子STING激动剂刺激巨噬细胞，树突细胞和/或肝非实质细胞中的先天细胞因子应答，从而抑制肝细胞中的HBV复制。 在其它实施方案中，本发明的方法可用于治疗慢性HBV感染。 本发明还提供鉴定用于治疗受试者中HBV感染的化合物的方法。

    EARLY DETECTION OF HEPATOCELLULAR CARCINOMA
    7.
    发明公开
    EARLY DETECTION OF HEPATOCELLULAR CARCINOMA 审中-公开

    公开(公告)号：EP4194003A1

    公开(公告)日：2023-06-14

    申请号：EP22211176.7

    申请日：2017-02-16

    申请人： Drexel University

    发明人： BLOCK, Timothy M. ,  WANG, Mengjun ,  MEHTA, Anand

    IPC分类号： A61K38/16 ,  C07K16/06 ,  G01N33/68 ,  G01N33/53 ,  G01N33/574

    摘要： Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.